Jennifer K. Simpson - 30 Jan 2023 Form 4 Insider Report for Panbela Therapeutics, Inc. (PBLA)

Role: President and CEO, Director
Signature: /s/ Joshua L. Colburn, Attorney-in-Fact
Issuer symbol: PBLA
Transactions as of: 30 Jan 2023
Transactions value $: $0
Form type: 4
Filing time: 01 Feb 2023, 15:37:17 UTC
Previous filing: 02 Mar 2022
Next filing: 09 Mar 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PBLA	Common Stock	Purchase		+4,444	+130%		7,868	30 Jan 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PBLA	Warrants (right to buy)	Purchase	$0	+8,888		$0	8,888	30 Jan 2023	Common Stock	8,888	$2.75	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reported securities purchased as one share of common stock and one warrant to purchase two shares of common stock for a combined price of $2.25 per share and warrant.
F2	On or after March 1, 2023, holder may elect an "alternative cashless exercise" pursuant to which they would receive an aggregate number of shares of common stock equal to 75% of the aggregate number of shares that would be issuable upon a cash exercise.